135 related articles for article (PubMed ID: 23453995)
21. Myeloperoxidase (MPO)-specific CD4+ T cells contribute to MPO-anti-neutrophil cytoplasmic antibody (ANCA) associated glomerulonephritis.
Gan PY; Holdsworth SR; Kitching AR; Ooi JD
Cell Immunol; 2013 Mar; 282(1):21-7. PubMed ID: 23665205
[TBL] [Abstract][Full Text] [Related]
22. Histologic and immunohistologic study and clinical presentation of ANCA-associated glomerulonephritis with correlation to ANCA antigen specificity.
Vizjak A; Rott T; Koselj-Kajtna M; Rozman B; Kaplan-Pavlovcic S; Ferluga D
Am J Kidney Dis; 2003 Mar; 41(3):539-49. PubMed ID: 12612976
[TBL] [Abstract][Full Text] [Related]
23. Coexistence of anti-GBM antibodies and MPO-ANCA in a patient with systemic vasculitis and crescentic glomerulonephritis.
Fernandes P; Lopes JA; Correia L; Gonçalves S; Jorge S
Nefrologia; 2010; 30(6):709-10. PubMed ID: 21113229
[No Abstract] [Full Text] [Related]
24. L27. Antibodies versus phenotypes: a clinician's view.
Jayne D
Presse Med; 2013 Apr; 42(4 Pt 2):579-82. PubMed ID: 23490640
[No Abstract] [Full Text] [Related]
25. L43. Seropositive and negative ANCA-associated vasculitis, anti-MPO and PR3-vasculitis: different outcomes?
Holle JU
Presse Med; 2013 Apr; 42(4 Pt 2):616-9. PubMed ID: 23481358
[No Abstract] [Full Text] [Related]
26. Extracapillary glomerulonephritis type I with the coexistence of positive anti-GBM and p-ANCA antibodies.
Toledo Perdomo K; Ortega Salas R; Pérez-Sáez MJ; Esquivias de Motta E; Espinosa Hernández M; López Andreu M; López Rubio F; Aljama García P
Nefrologia; 2011; 31(1):113-5. PubMed ID: 21270926
[No Abstract] [Full Text] [Related]
27. Expression of tumor necrosis factor receptors on granulocytes in patients with myeloperoxidase anti-neutrophil cytoplasmic autoantibody-associated vasculitis.
Hasegawa M; Nishii C; Ohashi A; Tomita M; Nakai S; Murakami K; Nabeshima K; Fujita Y; Ishii J; Hiki Y; Sugiyama S
Nephron Clin Pract; 2009; 113(3):c222-33. PubMed ID: 19690440
[TBL] [Abstract][Full Text] [Related]
28. Pathogenesis of ANCA-associated vasculitis: new possibilities for intervention.
Kallenberg CG; Stegeman CA; Abdulahad WH; Heeringa P
Am J Kidney Dis; 2013 Dec; 62(6):1176-87. PubMed ID: 23810690
[TBL] [Abstract][Full Text] [Related]
29. Complement system activation in ANCA vasculitis: A translational success story?
Kallenberg CG; Heeringa P
Mol Immunol; 2015 Nov; 68(1):53-6. PubMed ID: 26597208
[TBL] [Abstract][Full Text] [Related]
30. ANCA-positive pauci-immune rapidly progressive glomerulonephritis and the nephrotic syndrome.
Jabur WL; Saeed HM
Saudi J Kidney Dis Transpl; 2010 May; 21(3):526-30. PubMed ID: 20427883
[TBL] [Abstract][Full Text] [Related]
31. [NETs in pathogenesis of vasculitis].
Nakazawa D; Nishio S; Tomaru U; Atsumi T; Ishizu A
Nihon Jinzo Gakkai Shi; 2014; 56(2):117-23. PubMed ID: 24730349
[No Abstract] [Full Text] [Related]
32. Clinical and immunological features of drug-induced and infection-induced proteinase 3-antineutrophil cytoplasmic antibodies and myeloperoxidase-antineutrophil cytoplasmic antibodies and vasculitis.
Csernok E; Lamprecht P; Gross WL
Curr Opin Rheumatol; 2010 Jan; 22(1):43-8. PubMed ID: 19770659
[TBL] [Abstract][Full Text] [Related]
33. [A preliminary study of the significance of autoantibodies against light chain of myeloperoxidase on pulmonary damages in myeloperoxidase-antineutrophil cytoplasmic antibody associated vasculitis].
Zhang L; Shuai Z; Hu Z; Zhang M; Chen S
Zhonghua Nei Ke Za Zhi; 2015 Jun; 54(6):511-6. PubMed ID: 26359012
[TBL] [Abstract][Full Text] [Related]
34. Anti-endothelial cell antibodies in antineutrophil cytoplasmic antibodies negative pauci-immune crescentic glomerulonephritis.
Cong M; Chen M; Zhang JJ; Hu Z; Zhao MH
Nephrology (Carlton); 2008 Jun; 13(3):228-34. PubMed ID: 18315705
[TBL] [Abstract][Full Text] [Related]
35. L34. Neutrophils in ANCA-associated vasculitis: still under investigation.
Witko-Sarsat V
Presse Med; 2013 Apr; 42(4 Pt 2):595-7. PubMed ID: 23481359
[No Abstract] [Full Text] [Related]
36. FcγRIIB regulates T-cell autoreactivity, ANCA production, and neutrophil activation to suppress anti-myeloperoxidase glomerulonephritis.
Ooi JD; Gan PY; Chen T; Eggenhuizen PJ; Chang J; Alikhan MA; Odobasic D; Holdsworth SR; Kitching AR
Kidney Int; 2014 Dec; 86(6):1140-9. PubMed ID: 24869670
[TBL] [Abstract][Full Text] [Related]
37. Clinical analysis of patients with myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitis.
Shuai ZW; Lv YF; Zhang MM; Hu ZY
Genet Mol Res; 2015 May; 14(2):5296-303. PubMed ID: 26125725
[TBL] [Abstract][Full Text] [Related]
38. Bone marrow-derived cells are sufficient and necessary targets to mediate glomerulonephritis and vasculitis induced by anti-myeloperoxidase antibodies.
Schreiber A; Xiao H; Falk RJ; Jennette JC
J Am Soc Nephrol; 2006 Dec; 17(12):3355-64. PubMed ID: 17108314
[TBL] [Abstract][Full Text] [Related]
39. Pathogenesis of ANCA-associated vasculitides.
Kallenberg CG
Ann Rheum Dis; 2011 Mar; 70 Suppl 1():i59-63. PubMed ID: 21339221
[TBL] [Abstract][Full Text] [Related]
40. Myeloperoxidase antineutrophil cytoplasmic autoantibody-associated glomerulonephritis in a very elderly patient with generalized vasculitis at autopsy.
Nakamura C; Yorioka N; Nakanishi S; Naito T; Sugimoto N; Kanahara K; Mano M; Katayama S; Ishikawa K
Hiroshima J Med Sci; 1997 Sep; 46(3):99-104. PubMed ID: 9353970
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
